- Merck (MRK) says it has entered three separate collaboration agreements with Pfizer (PFE), Amgen (AMGN) and Incyte (INCY) to evaluate MRK's investigational MK-3475 immunotherapy cancer treatment, part of a new class of experimental drugs that unleash the body's immune system to target cancer cells.
- MRK will collaborate on studies of MK-3475 in combination with therapies from the other drugmakers; financial terms weren't provided about the collaborations.
- R&D chief Roger Perlmutter says MRK is looking at MK-3475 across a wide range of cancers, both as a standalone therapy and in combination with other treatments.
- Earlier: MRK net profits falls 14%.
From other sites
at Zacks.com (Thu, 8:55AM)
at 4-traders.com (Tue, 5:37PM)
at 4-traders.com (Tue, 5:01PM)
at Nasdaq.com (Mon, 12:12PM)
at Zacks.com (Mar 17, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs